Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials.

ABSTRACT:

Importance

Although anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration (AMD) results in improved vision overall, loss of substantial vision can occur. Understanding the processes that lead to loss of vision may lead to preventive strategies.

Objective

To determine the incidence, characteristics, causes, and baseline predictors of sustained visual acuity loss after 2 years of treatment with ranibizumab or bevacizumab for neovascular AMD.

Design, setting, and participants

A cohort study within a randomized clinical trial of participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Interventions

Participants were randomly assigned to treatment with ranibizumab or bevacizumab and to 2

SUBMITTER: Ying GS 

PROVIDER: S-EPMC4151260 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature